News | FDA | March 06, 2024

Ensight-AI Awarded FDA’s Breakthrough Device Designation for Its ECGVision-TTR Technology for Early Detection of ATTR-Cardiomyopathy

Ensight-AI, a Yale start-up and leader in AI-based cardiovascular diagnostics, announces the receipt of the U.S. Food and Drug Administration’s (FDA) Breakthrough Device Designation for their ECGvision-TTR Technology

Getty Images


March 6, 2024 — Ensight-AI, a Yale start-up and leader in AI-based cardiovascular diagnostics, announces the receipt of the U.S. Food and Drug Administration’s (FDA) Breakthrough Device Designation for their ECGvision-TTRTechnology for early detection of ATTR-Cardiomyopathy.  

Ensight-AI is leveraging the newly launched U.S. Food and Drug Administration’s (FDA) Breakthrough Devices Program, which provides patients with timely access to innovative medical devices.

ATTR-CM (ATTR Amyloid Cardiomyopathy) is a life-threatening condition which is often under-diagnosed due to nonspecific symptoms, and disproportionately affects Black individuals, highlighting the urgency for innovative diagnostic solutions like ECGvision-TTR. By bridging diagnostic disparities and improving access to care, ECGvision-TTR represents a pivotal advancement in healthcare equity.

Moreover, ECGvision-TTR paves the way for personalized care plans, enhancing the quality of life for individuals at risk of or suffering from ATTR-CM. I am immensely grateful for the opportunity the BDD program may provide us.”

ECGvision-TTR was developed through state-of-the-art deep learning algorithms and offers the unique ability to analyze 12-lead ECG images to detect signatures of ATTR Cardiomyopathy. This groundbreaking tool may empower clinicians with the ability to detect ATTR-CM at an early stage, enabling timely and effective interventions, ultimately leading to improved patient outcomes. The technology was developed in the Cardiovascular Data Science (CarDS) Lab by Dr. Rohan Khera, with Veer Sangha, a Yale graduate and Rhodes Scholar.

Ensight-AI was cofounded by Khera, Sangha, and Dr. Harlan Krumholz, the Harold H. Hines Professor of Medicine at Yale School of Medicine and a cardiologist.  

“ECGvision-TTR is a testament to Ensight-AI's commitment to leveraging cutting-edge technology to address unmet medical needs and improve patient care,” continued Khera.

For more information: www.yale.edu


Additional Content

News | ECG

Oct. 27, 2026 — Monebo Technologies and Innolitics have announced that the U.S. Food and Drug Administration (FDA) has ...

Home October 29, 2026
Home
Feature | ECG | Samir Awasthi, MD, PhD

For decades, medicine has treated the electrocardiogram as a familiar, inexpensive and indispensable test, but also as ...

Home June 16, 2026
Home
News | ECG

June 2, 2026 —HeartSciences Inc. has announced the commercial release of MyoVista Insights version 1.3, a major platform ...

Home June 05, 2026
Home
News | ECG

June 2, 2026 — AccurKardia, Inc. has been granted US Patent No. 12,620,488 for the company's proprietary machine ...

Home June 02, 2026
Home
News | ECG

May 7, 2026 — AccurKardia, a provider of ECG-based diagnostics technology, recently announced that AK+ Guard has been ...

Home May 08, 2026
Home
Subscribe Now